1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

AIMBLE

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2020

Location

Seoul South Korea

Primary Industry

Biotechnology

About

Founded in 2020 and based in Uijeongbu-si, South Korea, AIMBLE utilizes artificial intelligence to develop a new drug platform. The company operates business as a developer of new drug candidate materials based on artificial intelligence.
Current Investors
New Paradigm Investment, Schmidt, Korea Tech Incubator for Startup

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Healthcare IT, Medical Software
Website
www.aimble.com
Verticals
Artificial Intelligence
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.